Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,392,922
  • Shares Outstanding, K 56,348
  • Annual Sales, $ 3,150 K
  • Annual Income, $ -69,610 K
  • 60-Month Beta 1.98
  • Price/Sales 443.42
  • Price/Cash Flow N/A
  • Price/Book 4.92
Trade RYTM with:

Options Overview Details

View History
  • Implied Volatility 102.41% ( +5.89%)
  • Historical Volatility 89.06%
  • IV Percentile 52%
  • IV Rank 22.93%
  • IV High 244.01% on 06/13/22
  • IV Low 60.29% on 05/02/22
  • Put/Call Vol Ratio 0.02
  • Today's Volume 339
  • Volume Avg (30-Day) 333
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 12,462
  • Open Int (30-Day) 15,235

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.83
  • Number of Estimates 6
  • High Estimate -0.70
  • Low Estimate -1.03
  • Prior Year -0.85
  • Growth Rate Est. (year over year) +2.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.57 +16.32%
on 11/08/22
28.41 -11.69%
on 11/16/22
-1.28 (-4.85%)
since 10/28/22
3-Month
20.11 +24.76%
on 09/07/22
30.98 -19.01%
on 09/14/22
+3.07 (+13.94%)
since 08/29/22
52-Week
3.04 +725.33%
on 05/20/22
30.98 -19.01%
on 09/14/22
+15.85 (+171.54%)
since 11/26/21

Most Recent Stories

More News
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Lags Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 21.78% and 20.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

RYTM : 25.09 (+1.50%)
AFMD : 1.99 (-2.45%)
Earnings Preview: Solid Biosciences Inc. (SLDB) Q3 Earnings Expected to Decline

Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SLDB : 6.58 (-0.90%)
RYTM : 25.09 (+1.50%)
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q3 Earnings Expected to Decline

Rhythm Pharmaceuticals, Inc. (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RYTM : 25.09 (+1.50%)
SGEN : 117.37 (-3.18%)
Stocks Mixed As Fed Rate Hike Looms

September S&P 500 futures (ESU22) are moderately up +0.03% this morning after three major US benchmark indices bounced back during the regular session as an on-target inflation report mainly stopped the...

ESU22 : 3,871.24s (-0.79%)
APA : 46.59 (+3.63%)
RYTM : 25.09 (+1.50%)
IRNT : 0.4462 (-3.00%)
AKRO : 45.82 (+0.84%)
RIVN : 28.85 (+0.73%)
NEE : 82.49 (-1.48%)
FSR : 7.25 (+0.28%)
PANW : 170.51 (-0.51%)
ERIC : 6.12 (-1.13%)
3 Healthcare Stocks That Are Beating the Market

Here's why our roundtable is bullish on Shockwave Medical, Axsome Therapeutics, and Rhythm Pharmaceuticals.

SWAV : 249.74 (-2.93%)
AXSM : 70.84 (-5.22%)
RYTM : 25.09 (+1.50%)
Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study

Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.

ABBV : 158.20 (-0.15%)
RYTM : 25.09 (+1.50%)
ANVS : 12.86 (-0.69%)
PLRX : 19.52 (+0.31%)
Akero Therapeutics (AKRO) Up on Positive NASH Study Data

Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.

PFE : 49.49 (-0.16%)
HTGC : 14.03 (-0.07%)
RYTM : 25.09 (+1.50%)
AKRO : 45.82 (+0.84%)
What Bear Market? These 3 Stocks Have Been Rocketing Higher in 2022

These three healthcare stocks have defied the 2022 bear market.

COMP : 2.69 (-0.37%)
RYTM : 25.09 (+1.50%)
SIGA : 9.18 (+2.11%)
VERU : 5.52 (+1.85%)
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why

bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.

BLUE : 7.65 (+3.80%)
RYTM : 25.09 (+1.50%)
PLRX : 19.52 (+0.31%)
INZY : 1.4800 (+1.37%)
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment

Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.

AGLE : 1.2200 (-3.94%)
RYTM : 25.09 (+1.50%)
PLRX : 19.52 (+0.31%)
INZY : 1.4800 (+1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

3rd Resistance Point 26.74
2nd Resistance Point 26.08
1st Resistance Point 25.58
Last Price 25.09
1st Support Level 24.42
2nd Support Level 23.76
3rd Support Level 23.26

See More

52-Week High 30.98
Last Price 25.09
Fibonacci 61.8% 20.31
Fibonacci 50% 17.01
Fibonacci 38.2% 13.71
52-Week Low 3.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar